



AF

13/1  
10/23/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: SELLERS *et al.*

Application No.: 09/584,669

Group Art Unit: 1651

Filed: June 1, 2000

Examiner: M.V. Meller

For: THERAPEUTIC AND DIAGNOSTIC METHODS PENDENT ON CYP2A ENZYMES

AMENDMENT UNDER 37 CFR § 1.116

**BOX AF**  
Commissioner for Patents  
Washington, D.C. 20231

In response to the Office Action mailed July 2, 2002, please enter the following amendments and consider the following remarks intended to put this application into form for allowance. Applicants submit herewith: (a) Exhibit A, a marked up version of the claims showing the amendments made herein; and (b) Exhibit B, a list of claims that will be pending upon entry of the amendment.

IN THE SPECIFICATION:

Please amend the specification as follows: renumber page 52 to page 29a.

IN THE CLAIMS:

A marked up version of the claims showing the amendments is attached hereto as Exhibit A. Matter that has been deleted from claims 22 and 24 is indicated by brackets and matter that has been added to the claims is indicated by underlining. Please add new claims 35 and 36.

22. A method for enhancing the effectiveness of nicotine replacement therapy in an individual in need of such treatment consisting essentially of:

administering to an individual in need of nicotine replacement therapy a therapeutically effective amount of

(a) nicotine; and

(b) one or more substances selected from the group consisting of (i) substances which inhibit CYP2A activity; (ii) substances which inhibit transcription, and/or translation of the

*raises new issues*

RECEIVED

OCT 01 2002

TECH CENTER 1800/2900